Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Inclusion Criteria:

Part 1 and 2:

* Chinese participant who must be at least 20 years of age
* Documented multiple myeloma (MM) with measurable disease according to protocol-defined criteria
* Relapsed or refractory multiple myeloma after receiving at least 2 prior lines of therapy
* Eastern Cooperative Oncology Group performance status score of 0, 1, or 2
* Adequate recovery from prior therapy

Part 3:

* Chinese participants who must be at least 18 years of age
* Received both a proteasome inhibitor (PI) (greater than or equal to \[\>=\] 2 cycles or 2 months of treatment) and an immunomodulatory drug (IMiD) (\>=2 cycles or 2 months of treatment) in any order during the course of treatment (except for participants who discontinued either of these treatments due to a severe allergic reaction within the first 2 cycles/months)
* Documented evidence of progressive disease (PD) based on investigator's determination of response as defined by the International Myeloma Working Group (IMWG) criteria on or after their last regimen

Exclusion Criteria:

Part 1 and 2:

* Received daratumumab or other anti-CD38 therapies previously
* Previously received an allogenic stem cell transplant or has received an autologous stem cell transplantation within 12 weeks
* Exhibiting clinical signs of meningeal involvement of multiple myeloma
* Known chronic obstructive pulmonary disease, known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
* Known clinically significant cardiac disease
* Known to be seropositive for human immunodeficiency virus, hepatitis B or known to have a history of hepatitis C
* Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis
* Abnormal laboratory values according to protocol-defined parameters at screening

Part 3:

\- Received anti-myeloma treatment within 2 weeks before Cycle 1, Day 1